Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cediranib - AstraZeneca

Next Previous
X
Search
Drug Profile

Cediranib - AstraZeneca

Alternative Names: AZD-2171; Cediranib-maleate; Recentin; Zemfirza

Latest Information Update: 24 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Class Antineoplastics; Ethers; Fluorinated hydrocarbons; Indoles; Pyrrolidines; Quinazolines; Small molecules
  • Mechanism of Action Platelet-derived growth factor inhibitors; Proto-oncogene protein c-kit inhibitors; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists; Vascular endothelial growth factor receptor-3 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer; Glioblastoma
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Submission Withdrawal Ovarian cancer
  • Discontinued Acute myeloid leukaemia; Alveolar soft part sarcoma; Biliary cancer; Breast cancer; Cervical cancer; Colorectal cancer; Endometrial cancer; Fallopian tube cancer; Gastric cancer; Gastrointestinal stromal tumours; Glioblastoma; HER2 negative breast cancer; Malignant-mesothelioma; Non-small cell lung cancer; Peritoneal cancer; Prostate cancer; Renal cell carcinoma; Soft tissue sarcoma; Solid tumours

Most Recent Events

  • 24 Jul 2024 Discontinued - Phase-II for Alveolar soft part sarcoma (In adolescents, In children, Inoperable/Unresectable, Metastatic disease) in USA (PO) prior to July 2024 (AstraZeneca pipeline, July 2024)
  • 24 Jul 2024 Discontinued - Phase-II for Alveolar soft part sarcoma (In adolescents, In the elderly, Metastatic disease, In adults) in France, Italy, Germany (PO) prior to July 2024 (AstraZeneca pipeline, July 2024)
  • 24 Jul 2024 Discontinued - Phase-II for Alveolar soft part sarcoma (In adolescents, In the elderly, Metastatic disease, In adults) in United Kingdom, Spain, Australia (PO) prior to July 2024 (AstraZeneca pipeline, July 2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top